RNA-Based Therapies for Lung Diseases
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Biology".
Deadline for manuscript submissions: closed (15 April 2024) | Viewed by 1614
Special Issue Editor
Interests: cancer; molecular oncology; molecular medicine; targeted therapy; cell signaling; pulmonary diseases
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The development of new vectors, technologies, and delivery systems for nucleic acid transfer has led to a promising generation of gene therapy with less toxicity and side effects, and improved efficiency compared to those obtained in the “first” generation.
RNA has demonstrated strong potential as a candidate for nucleic acid-based therapeutics, and the ability to tackle previously "undruggable" targets. With the introduction of omics technologies, a deep understanding of RNA biology has been achieved, boosting the development of RNA therapeutics. Positive clinical trials results with RNA-based drugs have proven to be a promising strategy with a strong curative potential for the treatment of diverse diseases.
The application of RNA therapies for the treatment of pulmonary diseases is rapidly increasing due to the unique advantage of direct delivery of nucleic acids into the lung. Although there are still many obstacles to overcome to achieve safe clinical application, this strategy offers the possibility of treatment for a wide variety of respiratory system-related pathologies, including inflammatory lung diseases, fibrosis, and lung cancer.
This Special Issue will discuss the latest research findings on RNA-based gene therapies for pulmonary diseases with the aim of providing new insights into their future development.
We invite researchers to contribute original articles and reviews on the newly identified RNA-based therapies for the treatment of pulmonary diseases.
Dr. Marcella Barbarino
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
-
RNA-based therapy
- pulmonary diseases
- lung cancer
- COPD
- fibrosis
